Published in Mol Membr Biol on August 01, 2003
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A (2005) 3.18
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
The signal peptide of the Junín arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex. J Virol (2004) 1.74
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog (2009) 1.36
Lipids as modulators of membrane fusion mediated by viral fusion proteins. Eur Biophys J (2007) 1.29
Yeast sphingolipids: recent developments in understanding biosynthesis, regulation, and function. Biochim Biophys Acta (2006) 1.28
Cholesterol effectively blocks entry of flavivirus. J Virol (2008) 1.26
Ceramide, a target for antiretroviral therapy. Proc Natl Acad Sci U S A (2004) 1.22
Rapid membrane fusion of individual virus particles with supported lipid bilayers. Biophys J (2007) 1.08
Human immunodeficiency virus type 1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains. Retrovirology (2007) 1.08
Cubic phases in phosphatidylcholine-cholesterol mixtures: cholesterol as membrane "fusogen". Biophys J (2006) 1.03
Enhancement of enveloped virus entry by phosphatidylserine. J Virol (2005) 0.96
Murine coronavirus requires lipid rafts for virus entry and cell-cell fusion but not for virus release. J Virol (2005) 0.96
Parvovirus infection of cells by using variants of the feline transferrin receptor altering clathrin-mediated endocytosis, membrane domain localization, and capsid-binding domains. J Virol (2004) 0.96
Identification of an overabundant cholesterol precursor in hepatitis B virus replicating cells by untargeted lipid metabolite profiling. J Am Chem Soc (2009) 0.93
Targeting host factors: a novel rationale for the management of hepatitis C virus. World J Gastroenterol (2009) 0.93
Sphingolipids, cholesterol, and HIV-1: a paradigm in viral fusion. Glycoconj J (2006) 0.91
HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development. Vaccine (2008) 0.91
Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrob Agents Chemother (2013) 0.90
Elevated expression of GM3 in receptor-bearing targets confers resistance to human immunodeficiency virus type 1 fusion. J Virol (2004) 0.86
The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion. Virol J (2006) 0.85
Preferential invasion of mitotic cells by Salmonella reveals that cell surface cholesterol is maximal during metaphase. J Cell Sci (2013) 0.84
Canine distemper virus infection requires cholesterol in the viral envelope. J Virol (2007) 0.80
Lipid composition of viral envelope of three strains of influenza virus - not all viruses are created equal. ACS Infect Dis (2015) 0.79
A multiscale model for virus capsid dynamics. Int J Biomed Imaging (2010) 0.77
Common molecular mechanism of amyloid pore formation by Alzheimer's β-amyloid peptide and α-synuclein. Sci Rep (2016) 0.75
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A (2002) 4.48
High-throughput SHAPE analysis reveals structures in HIV-1 genomic RNA strongly conserved across distinct biological states. PLoS Biol (2008) 4.40
The HIV Env-mediated fusion reaction. Biochim Biophys Acta (2003) 3.37
Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene (2003) 2.71
XMRV: a new virus in prostate cancer? Cancer Res (2010) 1.95
Interactions of HIV-1 Gag with assembly cofactors. Biochemistry (2006) 1.83
PPPYVEPTAP motif is the late domain of human T-cell leukemia virus type 1 Gag and mediates its functional interaction with cellular proteins Nedd4 and Tsg101 [corrected]. J Virol (2003) 1.80
Selective and nonselective packaging of cellular RNAs in retrovirus particles. J Virol (2007) 1.79
Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol (2005) 1.76
Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol (2005) 1.75
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst (2009) 1.73
Interactions between HIV-1 Gag molecules in solution: an inositol phosphate-mediated switch. J Mol Biol (2006) 1.65
Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J Virol (2002) 1.64
Conformation of the HIV-1 Gag protein in solution. J Mol Biol (2006) 1.59
Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem (2006) 1.54
Structure and dynamics of micelle-associated human immunodeficiency virus gp41 fusion domain. Biochemistry (2005) 1.52
Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J Virol (2008) 1.50
HIV entry and envelope glycoprotein-mediated fusion. J Biol Chem (2012) 1.48
Nucleic acid binding and chaperone properties of HIV-1 Gag and nucleocapsid proteins. Nucleic Acids Res (2006) 1.47
Complex interactions of HIV-1 nucleocapsid protein with oligonucleotides. Nucleic Acids Res (2006) 1.47
Definition of a high-affinity Gag recognition structure mediating packaging of a retroviral RNA genome. Proc Natl Acad Sci U S A (2010) 1.46
Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry (2007) 1.46
Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol (2008) 1.41
Assembly properties of human immunodeficiency virus type 1 Gag-leucine zipper chimeras: implications for retrovirus assembly. J Virol (2008) 1.39
Mechanical properties of murine leukemia virus particles: effect of maturation. Biophys J (2006) 1.35
Late viral interference induced by transdominant Gag of an endogenous retrovirus. Proc Natl Acad Sci U S A (2004) 1.34
HIV-1 Gag extension: conformational changes require simultaneous interaction with membrane and nucleic acid. J Mol Biol (2010) 1.33
Murine T cells potently restrict human immunodeficiency virus infection. J Virol (2004) 1.32
mRNA molecules containing murine leukemia virus packaging signals are encapsidated as dimers. J Virol (2004) 1.28
Retrovirus-specific packaging of aminoacyl-tRNA synthetases with cognate primer tRNAs. J Virol (2002) 1.27
An unusual topological structure of the HIV-1 Rev response element. Cell (2013) 1.26
Identification of replication competent murine gammaretroviruses in commonly used prostate cancer cell lines. PLoS One (2011) 1.22
Role of murine leukemia virus nucleocapsid protein in virus assembly. J Virol (2004) 1.22
Ceramide, a target for antiretroviral therapy. Proc Natl Acad Sci U S A (2004) 1.22
Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis. Cancer Res (2008) 1.20
Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry (2005) 1.20
RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J Virol (2010) 1.18
On the role of the SP1 domain in HIV-1 particle assembly: a molecular switch? J Virol (2011) 1.17
Biochemical and biological studies of mouse APOBEC3. J Virol (2014) 1.14
Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J Infect Dis (2007) 1.13
Murine leukemia virus nucleocapsid mutant particles lacking viral RNA encapsidate ribosomes. J Virol (2002) 1.12
Quantitative measurement of fusion of HIV-1 and SIV with cultured cells using photosensitized labeling. Virology (2002) 1.12
Effects of blocking individual maturation cleavages in murine leukemia virus gag. J Virol (2004) 1.12
The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J Mol Biol (2004) 1.10
In vitro characterization of the interaction between HIV-1 Gag and human lysyl-tRNA synthetase. J Biol Chem (2006) 1.09
Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J Biol Chem (2006) 1.09
Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection. Bioconjug Chem (2009) 1.08
XMRV and prostate cancer--a 'final' perspective. Nat Rev Urol (2012) 1.08
Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. Biochemistry (2003) 1.07
Sphingomyelinase restricts the lateral diffusion of CD4 and inhibits human immunodeficiency virus fusion. J Virol (2007) 1.06
Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. J Biol Chem (2007) 1.06
Matrix domain modulates HIV-1 Gag's nucleic acid chaperone activity via inositol phosphate binding. J Virol (2010) 1.06
HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res (2008) 1.05
Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. J Virol (2008) 1.05
DESIGN OF LIPOSOMES CONTAINING PHOTOPOLYMERIZABLE PHOSPHOLIPIDS FOR TRIGGERED RELEASE OF CONTENTS. J Therm Anal Calorim (2009) 1.04
Progressive truncations C terminal to the membrane-spanning domain of simian immunodeficiency virus Env reduce fusogenicity and increase concentration dependence of Env for fusion. J Virol (2003) 1.03
Anticancer β-hairpin peptides: membrane-induced folding triggers activity. J Am Chem Soc (2012) 1.03
Multifunctional RNA nanoparticles. Nano Lett (2014) 1.03
Fundamental differences between the nucleic acid chaperone activities of HIV-1 nucleocapsid protein and Gag or Gag-derived proteins: biological implications. Virology (2010) 1.01
Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. J Virol (2005) 1.01
Reversible binding of recombinant human immunodeficiency virus type 1 gag protein to nucleic acids in virus-like particle assembly in vitro. J Virol (2002) 1.01
Preparation of recombinant HIV-1 gag protein and assembly of virus-like particles in vitro. Methods Mol Biol (2009) 1.00
C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion. J Biol Chem (2003) 0.99
HIV-1 gp41 transmembrane domain interacts with the fusion peptide: implication in lipid mixing and inhibition of virus-cell fusion. Biochemistry (2012) 0.99
Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide. Biochem Biophys Res Commun (2007) 0.99
Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. Retrovirology (2006) 0.98
Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother (2009) 0.98
Electrostatic interactions and binding orientation of HIV-1 matrix studied by neutron reflectivity. Biophys J (2010) 0.97
A novel class of photo-triggerable liposomes containing DPPC:DC(8,9)PC as vehicles for delivery of doxorubcin to cells. Biochim Biophys Acta (2010) 0.97
HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. J Leukoc Biol (2005) 0.97
Light-sensitive lipid-based nanoparticles for drug delivery: design principles and future considerations for biological applications. Mol Membr Biol (2010) 0.96
Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41. Biochemistry (2004) 0.96
Sphingolipids: modulators of HIV-1 infection and pathogenesis. Biosci Rep (2005) 0.96
Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). J Control Release (2011) 0.96
Photoinduced reactivity of the HIV-1 envelope glycoprotein with a membrane-embedded probe reveals insertion of portions of the HIV-1 Gp41 cytoplasmic tail into the viral membrane. Biochemistry (2008) 0.95
Identification of HIV-1 nucleocapsid protein: nucleic acid antagonists with cellular anti-HIV activity. Biochem Biophys Res Commun (2002) 0.95
Encapsidation and transduction of cellular genes by retroviruses. Front Biosci (2003) 0.94
Acid-induced changes in thermal stability and fusion activity of influenza hemagglutinin. Biochemistry (2002) 0.93
An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T-cells. AIDS (2004) 0.93
A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. AIDS (2006) 0.93